GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Cash per Share

BioLine Rx (BioLine Rx) Cash per Share : $0.59 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). BioLine Rx's Cash per Share for the quarter that ended in Dec. 2023 was $0.59.


BioLine Rx Cash per Share Historical Data

The historical data trend for BioLine Rx's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Cash per Share Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 0.97 1.20 0.83 0.59

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.83 0.70 0.53 0.40 0.59

BioLine Rx Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

BioLine Rx's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

BioLine Rx's Cash per Share for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLine Rx  (NAS:BLRX) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.


BioLine Rx Cash per Share Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (BioLine Rx) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (BioLine Rx) Headlines

From GuruFocus